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Background: The naturally occurring alkaloid drug, quinine is commonly used for the treatment of severe malaria.
Despite centuries of use, its metabolism is still not fully understood, and may play a role in the haemolytic disorders
associated with the drug.
Methods: Incubations of quinine with CYPs 1A2, 2C9, 2C19, 2D6, and 3A4 were conducted, and the metabolites
were characterized by accurate mass UPLC-MSE analysis. Reactive oxygen species generation was also measured in
human erythrocytes incubated in the presence of quinine with and without microsomes.
Results: The metabolites 3-hydroxyquinine, 2’-oxoquininone, and O-desmethylquinine were observed after
incubation with CYPs 3A4 (3-hydroxyquinine and 2’-oxoquininone) and 2D6 (O-desmethylquinine). In addition,
multiple hydroxylations were observed both on the quinoline core and the quinuclidine ring system. Of the five
primary abundance CYPs tested, 3A4, 2D6, 2C9, and 2C19 all demonstrated activity toward quinine, while 1A2 did
not. Further, quinine produced robust dose-dependent oxidative stress in human erythrocytes in the presence of
microsomes.
Conclusions: Taken in context, these data suggest a CYP-mediated link between quinine metabolism and the
poorly understood haemolytic condition known as blackwater fever, often associated with quinine ingestion.
Keywords: Quinine, Blackwater fever, Metabolism, CYP450, Metabolite identificationBackground
Usage of the alkaloid anti-malarial agent, quinine to treat
resistant strains of Plasmodium falciparum and as an
intravenous treatment for severe malaria has increased
over the past few decades [1-4]. Several in vitro and
in vivo studies have reported numerous metabolites of
quinine, including 3-hydroxyquinine, O-desmethylquinine,
and 2’-oxoquininone and speculations have been made
concerning their origins. However, the CYP 450 enzymes
responsible for their formation have yet to be identified
[4-8]. For example, inhibition studies have indicated that* Correspondence: brandon.s.pybus.mil@mail.mil
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reproduction in any medium, provided the or3-hydroxyquinine production may be CYP 3A4 mediated
[4,9,10]. However, Wanwimolruk et al. have shown that,
while pretreatment with the CYP 3A4 inducer, rifampin
seemed to enhance quinine clearance, no appreciable
changes in 3-hydroxyquinine formation were noted after
such treatment [4,8]. In order to address some of these in-
consistencies in the literature, a set of in vitro experiments
were undertaken to unambiguously assign the metabolites
of quinine produced by each of the five primary abun-
dance CYPs (1A2, 3A4, 2C9, 2C19, and 2D6).
Quinine treatment is associated with several adverse
events which may have a significant metabolism compo-
nent. One of the least understood and most severe is
blackwater fever (BWF), a haemolytic disorder charac-
terized by massive amounts of haemoglobin in the urine.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and irregular quinine ingestion [11]. Although quinine is
not traditionally thought of as an oxidant drug, recent data
suggest a link between quinine ingestion, glucose-6-phos-
phate dehydrogenase (G6PD) deficiency, malaria infection,
and the occurrence of BWF [12,13]. Further, Bloom et al.
reported that after incubation with microsomes and quin-
ine, reduced glutathione (GSH) depletion was comparable
to that of primaquine [14]. It is reasonable to assume that
the metabolic formation of quinine, quinolones, could
add low levels of oxidative stress, which combined with
the background oxidative environment of a parasitized
G6PD-deficient erythrocyte, may lead to the haemolytic
response associated with BWF. To this end, attempts to
identify novel metabolites, quinolone or otherwise,




Chemicals used were: quinine (Sigma, St Louis, MO, USA,
# 6119-47-7), nicotinamide adenine dinucleotide phos-
phate, oxidized form (NADP) (Sigma, # 077K7000), aceto-
nitrile (Fisher Scientific, Waltham, MA, USA, #972970),
glucose-6-phosphate (G6P) (Sigma, # 046K3779), glucose-
6-phosphate dehydrogenase (G6PD) (Sigma, # 068K3795),
and magnesium chloride (MgCl2) (Sigma, #102K0154).
Mobile phases were made with HPLC grade water,
acetonitrile, and formic acid. The ROS probe 2,
7-dichlorofluorescein diacetate (DCFDA) was obtained
from Molecular Probes/Invitrogen, (Eugene, OR, USA).
CYP incubations
In vitro metabolism studies with isoenzymes were
conducted according to the manufacturer’s instructions
(BD Gentest, San Jose, CA, USA). Briefly, the procedure
was as follows. A 30 μl aliquot of 5 mg/ml isoenzyme, ei-
ther CYP 1A2, 3A4, 2C9, 2C19, or 2D6, was mixed with
NADPH regeneration system A (50 μl) and B (10 μl), and
990 ml phosphate buffer (pH 7.4, 100 mM) was added.
The solution was mixed gently by pipetting and incubated
at 37°C for about 2 min, and then the test compound,
quinine (10 μM final concentration), was added. A portion
of the mixture (120 μl) was then collected at several time
points (0, 60 min) followed by quenching with an equal
volume of acetonitrile. The samples were vortexed for
30 sec, and centrifuged at 13,600 g at 4°C for 10 min.
Supernatant was collected and loaded onto 96-well
plates (200 μl/well) for LC-MS analysis.
Accurate mass metabolite identification
Quinine samples were analysed using a Waters (Milford,
MA, USA) Acquity UPLC system coupled to a Xevo Q-ToF
mass spectrometer equipped with a standard electrosprayionization source. Chromatographic separations were
achieved using a Waters Acquity BEH C18 1.7 μm 2.1
mm x 100 mm column with a 2 to 98% acetonitrile gradi-
ent over 6.10 min at a flow rate of 0.70 mL/min. Mobile
phase A consisted of 10 mM ammonium bicarbonate and
mobile phase B consisted of acetonitrile. The gradient
consisted of phase B increasing from 2 to 60% in the time
period of 0 to 2.9 min, followed by 60 to 98% from 2.9 to
4.7 min, holding at 98% B from 4.7 to 5.2 min, and then
returning to 2% B from 5.2 to 6.1 min. MS conditions
were optimized for quinine detection in the positive
electrospray mode with the corresponding instrumental
parameters: capillary 3 kV, sampling cone 35 V, extrac-
tion cone 4 V, source temperature 120°C, desolvation
temperature 550°C, cone gas flow 30 L/Hr, and
desolvation gas flow 1,000 L/hr. Low energy MS scans
were conducted using a collision energy of 6 V. Quinine
fragments were produced using the MSE mode with a
collision energy ramp from 30–35 V. Quinine metabo-
lites were indentified and analysed using Waters
Metabolynx software, MSE, and MS/MS analysis.
Reactive oxygen species (ROS) formation kinetics assay
The intra-erythrocytic formation of ROS was moni-
tored in real-time with 2’7’- dichlorofluorescein
diacetate (DCFDA), a fluorescent ROS probe as described
earlier [15]. Human erythrocytes that had been collected
in citrate phosphate anticoagulant were used. The erythro-
cytes were washed twice with 0.9% saline and suspended
in PBSG at a haematocrit of 10%. A 60 mM stock of
DCFDA was prepared in DMSO and added to the eryth-
rocytes suspension to obtain the final concentration of
600 mM. The suspension containing 600 mM of DCFDA
was incubated at 37°C for 20 min and centrifuged at 1,000
g for 5 min. The pellet of DCFDA-loaded erythrocytes
was suspended in PBSG to 50% haematocrit and used
for kinetic ROS formation assay. The microsomal
metabolism-linked assay was directly set up in a clear flat-
bottomed, 96-well microplate. The reaction mixture
contained 40 ml of DCFDA-loaded erythrocytes, 40 ml
NADPH regeneration cocktail (0.8 mmol NADP+, 5 mmol
G6P, 3 mmol MgCl2 and 0.2 units G6PD), 40 ml KCl (31
mmol), 10 ml of pooled human liver microsomes (25 pmol
CYP content), 2 ml of quinine (concentration as presented
below) and potassium phosphate buffer (100 mM, pH
7.4), to make up the final volume to 200 ml. The controls
without drug (with and without microsomes) were also set
up simultaneously. Each assay was set up at quadruplicate.
The plate was immediately placed in a microplate reader
programmed to kinetic measurement of fluorescence
(excitation 488 nm and emission 535 nm) for 2 hr with 5-
min time intervals. The results are presented as increase
in time-dependent fluorescence by quinine with and with-
out microsomes.
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In order to determine the specific metabolites likely to be
formed physiologically by each of the five primary abun-
dance CYPs (1A2, 3A4, 2C9, 2C19, and 2D6), 1-hr incuba-
tions with quinine were conducted and the subsequent
metabolites formed were analysed by accurate mass
UPLC-MSE. Table 1 summarizes the metabolites observed
with each CYP and Figures 1 and 2 show the correspon-
ding MSE spectra for each metabolite. In general, four
types of metabolites were observed; hydroxylations on the
quinoline core, hydroxylations on the quinuclidine ring,
demethylations, and ketones. Further, at the concentra-
tions chosen in this study, 3A4 metabolized quinine most
extensively, followed by 2C19, 2C9, and 2D6. CYP 1A2
showed very little appreciable activity towards quinine,
with only trace amounts of a demethylated metabolite be-
ing observed after 60 min. Assignments of localization for
each biotransformation to either the quinoline core or
quinuclidine ring were made by MSE fragmentation. Spe-
cific variants of each subtype of metabolite observed are
discussed in more detail below.
Modifications on the quinuclidine ring
MSE analysis of the quinine metabolites detected re-
vealed that two portions of quinine were modified: the
quinuclidine ring and quinoline core. This section will
focus on the quinuclidine ring and the results for each
ring metabolite are illustrated in Figure 1. The MSE frag-
mentation pattern of unmodified quinine is illustrated in
Figure 1A and shows the different fragmentations of
quinine produced upon MSE fragmentation. These frag-
ments encompassed the entire molecule and allowed for
the localization of chemical modifications to quinine.
After incubation with CYP 3A4, multiple metabolites
were observed with an m/z of 341.18. As represented inTable 1 Quinine metabolites formed upon CYP 3A4, 2D6, 2C1
observed with each corresponding CYP
Metabolite observed
Metabolite 3A4 2D6 2C19 2C9 1A2
Parent + + + + +
Ketone + - + - -
Hydroxylation + + + + -
Hydroxylation + + + + -
Hydroxylation + + + + -
Hydroxylation/Ketone tautomers + - + + +
Demethylation + hydroxylation + - - - -
Demethylation + + + + +
2x Hydroxlyation + - - - -
2x Hydroxlyation + - - - -
The plus and minus signs indicate whether the listed metabolite was observed with
observed and retention times (tr) for each metabolite are listed. The relative % of eTable 1, the predominant metabolite was observed at
2.85 min. MSE fragmentation showed mass changes of +
16 Da to quinuclidine ring fragments which was consist-
ent with the addition of a hydroxyl group (Figure 1B).
Given the relative intensity of this metabolite, it was ten-
tatively assigned as 3-hydroxyquinine. This metabolite
was observed to a lesser extent after incubation with
CYPs 2C9, 2C19, and 2D6. Two other metabolites with
the same observed m/z (341.18), retention times of 2.69
and 2.94 min, and MSE fragmentation consistent with
the addition of a hydroxyl group on the quinuclidine
ring (as described above) were noted after incubation
with all CYPs tested except 1A2 (data not shown). In
addition to single hydroxylations of the quinuclidine
ring, incubations with CYP 3A4 also resulted in the ap-
pearance of a metabolite with retention time of 2.41 min
and an observed m/z of 357.18. The + 32 Da shift was lo-
calized to quinuclidine ring fragments as illustrated in
Figure 1C.
In addition to mass changes consistent with hydroxy-
lations, one metabolite appeared at 3.12 min with an ob-
served m/z of 339.17. This metabolite appeared with
CYP 3A4 and 2C19 quinine incubations. The + 14 Da
mass increase is consistent with the addition of a hy-
droxyl followed by desaturation to the corresponding ke-
tone. The MSE fragmentation pattern for this metabolite
is shown in Figure 1D and indicates a mass change in
one quinuclidine ring fragment (m/z 321.16). This frag-
mentation pattern is consistent with a ketone-forming
alpha to the nitrogen of the quinuclidine ring. Several
other metabolites with an m/z of 339.17 were observed,
however, these were not of ample intensity to make a de-
finitive determination as to the location of these modifi-
cations. It should be noted that this ketone is unlikely to
be on the quinoline core as this modification would have9, 2C9 and 1A2 incubation Shown are the metabolites
MS information Relative % metabolite present
m/z Tr (min) 3A4 2D6 2C19 2C9 1A2
325.19 3.6 49.04 95.19 78.22 93.90 99.31
339.17 3.12 0.27 0.00 0.09 0.00 0.00
341.18 2.69 0.43 0.66 1.22 0.06 0.00
341.18 2.85 44.88 0.98 8.36 0.72 0.00
341.18 2.94 2.22 1.47 10.89 5.20 0.00
341.18 3.14 0.32 0.00 0.01 0.01 0.06
327.18 2.48 0.16 0.00 0.00 0.00 0.00
311.17 3.16 0.15 1.70 1.23 0.10 0.62
357.18 2.57 1.18 0.00 0.00 0.00 0.00
357.18 2.41 1.36 0.00 0.00 0.00 0.00
each CYP after 60 minute incubations. The corresponding m/z values
ach metabolite formed is also listed.
m/z
172.07
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Figure 1 MSE identification of quinine quinuclidine ring metabolites. Shown in panels A-D are the corresponding MSE spectra (i) for quinine
and each quinine quinuclidine ring metabolite. The m/z values for each ion are indicated as well as the assigned quinine fragment. The assigned
metabolite structures are shown in (ii). The observed parent ion m/z, mass error, and CYPs responsible for production of each metabolite are
indicated under each structure.
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served must occur somewhere on the quinuclidine ring.
Modifications on the quinoline core
The quinoline core of quinine was also modified upon
incubation with the various CYPs. Incubations with ei-
ther CYP 3A4, 2C19, or 2C9 resulted in the appearanceof a metabolite with a retention time of 3.06 min and an
observed m/z of 341.17. The MSE fragmentation pattern
for this metabolite is shown in Figure 2A and the +16
Da mass shift is consistent with the addition of a hy-
droxyl group to the quinoline core. This metabolite was
tentatively assigned as the 2’ hydroxylated form of qui-
nine. It should be noted that by accurate mass and MSE
Tentative Metabolite
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Figure 2 MSE identification of quinine quinoline core metabolites. Shown in panels A-D are the corresponding MSE spectra (i) for each
quinine quinoline core metabolite. The m/z values for each ion are indicated as well as the assigned quinine fragment. The assigned metabolite
structures are shown in (ii). The observed parent ion m/z, mass error, and CYPs responsible for production of each metabolite are indicated under
each structure.
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its expected tautomer (2’–oxoquininone). Further, a me-
tabolite appeared after CYP 3A4 incubation at a reten-
tion time of 2.57 min with an m/z of 357.17 consistent
with the addition of two hydroxyl groups (+ 32 Da).
MSE fragmentation patterns indicated that one of these
hydroxylations occurs on the quinoline core, with the
other occurring on the quinuclidine ring as shown in
Figure 2B. In addition to the hydroxylated metabolites
described above, all CYPs tested generated a metabolite
with a retention time of 2.48 min and an observed m/z
of 311.17. This peak was assigned to the structure in
which the 6’ methoxy has been demethylated (− 14 Da).
MSE fragmentation of this metabolite is shown in
Figure 2C and confirms the loss of a methyl group to all
fragments associated with the quinoline core. Although
CYP 2D6 generated the most of this metabolite underthese experimental conditions, all CYPs tested generated
detectable amounts of this metabolite. It should be
noted that the primary purpose of the present study was
to identify the number and type of CYPs involved in
quinine clearance and not to attribute relative contribu-
tions from each in vivo. Further, as with 2’ hydroxy-
lation, this metabolite is indistinguishable by accurate
mass or MSE fragmentation from its expected tautomer
(6’-oxoquininone).
ROS formation kinetics assay
Having established from CYP incubations and MS ana-
lysis that quinine forms metabolites that have the poten-
tial to redox cycle and create oxidative stress, the ability
of quinine to produce ROS was assayed and the results
illustrated in Figure 3. Quinine was assayed in normal
human erythrocytes in the presence and absence of
Figure 3 Time/Concentration-dependent oxidative stress
produced in normal human erythrocytes by microsomal
metabolites of quinine in vitro. Plotted are the changes in relative
fluorescence units (RFU) for various quinine concentrations as a
function of time A.) without human liver microsomes (HLM) and B.)
with HLM. C.) Concentration dependence of ROS generation at 60
min is plotted. Each point represents values mean ± SD of
four observations.
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noticeable oxidative stress in normal human erythrocytes
without microsomes as indicated by no significantincrease in DCFDA fluorescence. However, incubation of
human erythrocytes with quinine in presence of human
liver microsomes produced robust reactive oxidative stress
as indicated by time-dependent increase in DCFDA fluo-
rescence. These observations indicate that quinine meta-
bolites generated through CYP-mediated pathways are
responsible for producing intracellular oxidative stress in
the erythrocytes. Further, the increase in ROS production
by the microsomal metabolites of quinine was observed to
be concentration dependent (Figure 3).
Conclusions
The cinchona alkaloid anti-malarial agent, quinine is ex-
tensively metabolized in vivo, and many of the resulting
metabolites have been reported both in urine and
plasma [4,7,8,16]. While these studies have largely used
synthetic metabolites of the diasteriomer quinidine as
reference standards for HPLC identification rather than
direct observation via accurate mass MS, the consensus
assignments are not in question. However, ambiguity re-
mains concerning the specific CYP pathways responsible
for the production of the major metabolites, and there-
fore the primary clearance routes of this drug. For ex-
ample, Wanwimolruk et al. observed that both cigarette
smoking and rifampin pretreatment enhance the clea-
rance of quinine, suggestive of important roles for both
CYP3A and 1A families in quinine clearance. They fur-
ther noted that neither observation correlated with a sig-
nificant increase in the ratio of 3-hydroxyquinine, a
major metabolite, in the urine [4,8]. Other metabolites
have been observed in urine such as 2’-oxoquininone
and O-desmethylquinine which have not been assigned
to specific CYP pathways [6,7,16].
In the present study, CYP 3A4 was identified as
predominantly responsible for the production of 3-
hydroxyquinine, and a second hydroxylation localized to
the quinoline core. To date, the only hydroxylation
reported on the quinoline core occurred at the 2’ position,
therefore this metabolite most likely corresponds to 2’-
hydroxyquinine. It is important to note that the tauto-
meric quinolone form of this metabolite is isobaric, but is
assumed to exist for this metabolite and all others in
which hydroxylation occurs on the quinoline core. Three
other keto metabolites were observed after incubation
with CYP 3A4, one of which localized to the quinuclidine
ring, as determined by MSE, and the others which had
fragmentation patterns with insufficient signal intensity
for accurate localization. However, the m/z associated with
each of these ketone metabolites was only consistent with
addition to the quinuclidine ring. CYP3A4 was also found
to mediate the production of two doubly hydroxylated
metabolites, one in which hydroxylation occurred both
on the quinoline core and the quinuclidine ring (2’,
3-dihydroxyquinine is the most likely possibility for
Figure 4 Summary of quinine metabolism. Shown are the identified metabolites of quinine and their predicted redox active forms. The CYPs
responsible for each transformation are indicated for each pathway and the CYPs primarily responsible for each transformation are indicated in
green. Several other metabolites are listed for which the structures are not shown (3-hydroxyquinine, 6-hydroxyquinine, N-oxide, and
multiply hydroxylated).
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ring on the quinuclidine ring. Given the abundance in
plasma of 3-hydroxyquinine, it is reasonable to assume
that hydroxylation at the 3 position accounts for one of
these, while the other hydroxylation may occur alpha to
the nitrogen at the 6 position on the quinuclidine ring.
This would correspond to the reported dihydroxy non-
phenolic metabolite reported by Brodie et al. [16]. While
O-demethylation was observed after incubation with all
five CYPs tested, under these experimental conditions
CYP 2D6 produced the most of this metabolite followed
by 2C19, 3A4, 1A2, and 2C9 respectively. Further, CYP
3A4 was found to catalyze hydroxylation of this metabo-
lite, presumably at the 2’ position for the reasons discussed
above. Lastly, two other hydroxylated species were ob-
served, which were generated at various levels with CYPs
3A4, 2D6, 2C9, and 2C19. As stated above, one of these
would presumably be the substitution alpha to the
quinuclidine nitrogen atom reported by Brodie et al.,
while the other would seem to be an as yet unidentified
metabolite [16]. A schematic representation of the major
phase I metabolic pathways elucidated from this work is
provided (Figure 4).
Bloom et al. reported GSH depletion after incubation
with microsomes and quinine, comparable to levels of
known oxidant drugs [14]. Interestingly, recent data sug-
gest quinolone drugs have the capacity to generate react-
ive oxygen species in the presence of human liver
microsomes, and in fact have been shown to reduce gluta-
thione levels in rat liver [17,18]. Fluoroquinolone drugs
are also often associated with a haemolytic anaemia whichmay in some ways be similar to the haemolysis seen with
blackwater fever [19-23]. Further, a strong correlation bet-
ween BWF and G6PD deficiency has been established
[12,13]. Oxidant molecules cause accelerated generation
and accumulation of reactive oxygen intermediates (super-
oxide radical, hydroxyl radical and hydrogen peroxide) in
the erythrocytes [24]. In the present study, it was clearly
shown that products of CYP-mediated quinine metabo-
lism generate robust, dose-dependent oxidative stress in
human erythrocytes (Figure 3). This may in part be due to
redox cycling of the quinone species observed after incu-
bation with CYP 3A4 (Figure 4). This would become in-
creasingly important in individuals with already high
backgrounds of oxidative stress, such as those infected
with malaria or with a genetic deficiency such as G6PD
deficiency. It is reasonable to speculate that quinine me-
tabolites rather than quinine itself are at least partially res-
ponsible for the haemolytic oxidative stress associated
with BWF. While the pathogenesis of BWF is incom-
pletely understood, the metabolite identification outlined
here identifies a class of molecules that warrant further in-
vestigation, specifically regarding the ability of these spe-
cies to generate oxidative stress in the erythrocyte.
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